Abstract
The diagnosis of osteoarthritis (OA) is currently based on clinical presentation and radiographic signs. However, because radiographic diagnosis is based on decreased joint space, it detects disease only after considerable cartilage damage has occurred. Yet, there is only a modest correlation between the extent of structural damage in the osteoarthritic joint and the pain and functional impairment that causes the patient to seek treatment. Still, there remains a fundamental belief that if further joint damage could be prevented, disease progression would be stopped, and if joint damage could be reversed, functionality would be restored. All of this means that a method of measuring disease activity in OA is critically important for rationalizing treatment of OA. A knowledge of disease activity is required for determining the need of treatment, the mode of treatment and the effectiveness of treatment. Ideally, this is a role for a molecular marker.*
Chapter PDF
References
Garnero, P., J.-C. Rousseau, and P.D. Delmas. 2000. Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases. Arthritis Rheum. 43:953–968.
Greenwald, R.A. 1996. Review: Monitoring collagen degradation in patients with arthritis: the search for suitable surrogates. Arthritis Rheum. 39:1455–1465.
Heinegård, D. and T. Saxne. 1991. Molecular markers of processes in cartilage in joint disease. Br. J. Rheumatol. 30 (Suppl.):21–4.
Lohmander, L.S. 1997. What is the current status of biochemical markers in the diagnosis, prognosis and monitoring of osteoarthritis? Baillieres Clin. Rheum. 11:711–726.
Lohmander, L.S. and D.T. Felson. 1997. Defining the role of molecular markers to monitor disease, intervention, and cartilage breakdown in osteoarthritis. J. Rheumatol. 24:782–785.
Poole, A.R. 1994. Immunochemical markers of joint inflammation, skeletal damage and repair: Where are we now? Ann. Rheum. Dis. 53:3–5.
Ala-Kokk, L., C.T. Baldwin, R.W. Moskowitz, and D.J. Prockop. 1990. Single base mutation in the type II procollagen gene (COL2A1) as a cause of primary osteoarthritis associated with a mild chondrodysplasia. Proc. Natl. Acad. Sci. USA 87:6565–6568.
Pun, Y.L., R.W. Moskowitz, S. Lie, W.R. Sundstrom, S.R. Block, C. McEwen, et al. 1994. Clinical correlations of osteoarthritis associated with a single-base mutation (arginine519 to cysteine) in type II procollagen gene: a newly defined pathogenesis. Arthritis Rheum. 37:264–269.
Horton, W.E., Jr., M. Lethbridge-Cejku, M.C. Hochberg, R. Balakir, P. Precht, C.C. Plato, et al. 1998. An association between an aggrecan polymorphic allele and bilateral hand osteoarthritis in elderly white men: data from the Baltimore Longitudinal Study of Aging (BLSA). Osteoarth. Cart. 6:245–251.
Meulenbelt, I., C. Bijkerk, S.C. de Wildt, H.S. Miedema, H.A. Valkenburg, F.C. Breedveld, et al. 1997. Investigation of the association of the CRTM and CRTL1 genes with radiographically evident osteoarthritis in subjects from the Rotterdam study. Arthritis Rheum. 40:1760–1765.
Meulenbelt, I., C. Bijkerk, H.S. Miedema, F.C. Breedveld, A. Hofman, H.A. Valkenburg, et al. 1998. A genetic association study of the IGF-1 gene and radiological osteoarthritis in a population-based cohort study (the Rotterdam Study). Ann. Rheum. Dis. 57:371–374.
Meulenbelt, I., C. Bijkerk, S.C. de Wildt, H.S. Miedema, F.C. Breedveld, H.A. Pols, et al. 1999. Haplotype analysis of three polymorphisms of the COL2A1 gene and associations with generalised radiological osteoarthritis. Ann. Human Genet. 63:393–400.
Oliveria, S.A., D.T. Felson, P.A. Cirillo, J.I. Reed, and A.M. Walker. 1999. Body weight, body mass index, and incident symptomatic osteoarthritis of the hand, hip, and knee. Epidemiology 10:161–166.
Silveri, F., D. Brecciaroli, F. Argentati, and C. Cervini. 1994. Serum levels o1 insulin in overweight patients with osteoarthritis of the knee [see comments]. J. Rheumatol. 21:1899–1902.
Denko, C.W., B. Boja, and R.W. Moskowitz. 1994. Growth promoting peptides in osteoarthritis and diffuse idiopathic skeletal hyperostosis: insulin, insulin-like growth factor-I, growth hormone. J. Rheumatol. 21:1725–1730.
Zhang, Y., T.E. McAlindon, M.T. Hannan, C.E. Chaisson, R. Klein, Y.W. Wilson, et al. 1998. Estrogen replacement therapy and worsening of radiographic knee osteoarthritis: the Framingham Study. Arthritis Rheum. 41:1867–1873.
Lane, N.E., L.R. Gore, S.R. Cummings, M.C. Hochberg, J.C. Scott, E.N. Williams, et al. 1999. Serum vitamin D levels and incident changes of radiographic hip osteoarthritis: a longitudinal study. Study of Osteoporotic Fractures Research Group. Arthritis Rheum. 42:854–860.
Otterness, I.G., R.O. Zimmerer, A.C. Swindell, A.R. Poole, D. Heinegård, T. Saxne, et al. 1995. An examination of some molecular markers in blood and urine for discriminating patients with osteoarthritis of the knee from normal individuals. Acta Orthop. Scand. 66 (Suppl. 266):148–150.
Otterness, I.G., A.C. Swindell, R.O. Zimmerer, A.R. Poole, M. lonescu, and L. Weiner. 2000. Analysis of 14 molecular markers for monitoring osteoarthritis. Segregation of the markers into clusters and distinguishing osteoarthritis at baseline. Osteoarth. Cart. 8:180–185.
Lohmander, L.S., L. Dahlberg, D. Eyre, M. Lark, E.J. Thonar, and L. Ryd. 1998. Longitudinal and cross-sectional variability in markers of joint metabolism in patients with knee pain and articular cartilage abnormalities. Osteoarth. Cart. 6:351–361.
Billinghurst, R.C., L. Dahlberg, M. Ionescu, A. Reiner, R. Bourne, C. Rorabeck, et al. 1997. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J. Clin. Inv. 99:1534–1545.
Otterness, I.G., J.T. Downs, C. Lane, M.L. Bliven, H. Stukenbrok, D.N. Scampoli, et al. 1999. Detection of collagenase-induced damage of collagen by 9A4, a monoclonal C-terminal neoeptiope antibody. Matrix Biol. 18:331–341.
Atley, L.M. J.S. Mort, M. Lalumiere, and D.R. Eyre. 2000. Proteolysis of human bone collagen by cathepsin K: characterization of the cleavage sites generating by cross-linked N-telopeptide neoepitope. Bone 26:241–247.
Dodge, G.R., I. Pidoux, and A.R. Poole. 1991. The degradation of type II collagen in rheumatoid arthritis: an immunoelectron microscopic study. Matrix 11:330–338.
Hollander, A.P., T.F. Heathfield, C. Webber, Y. Iwata, R. Bourne, C. Rorabeck, et al. 1994. Increased damage to type II collagen in osteoarthritic articular cartilage detected by a new immunoassay. J. Clin. Inv. 93:1722–1732.
Dodge, G.R. and A.R. Poole. 1989. Immunohistochemical detection and immunochemical analysis of type II articular cartilages and in explants of bovine articular cartilage cultured with interleukin 1. J. Clin. Invest. 83:647–661.
Srinivas, G.R., H.J. Barrach, and C.O. Chichester. 1993. Quantitative immunoassays for type II collagen and its cyanogen bromide peptides. J. Immunol. Method 159:53–62.
Srinivas, G.R., C.O. Chichester, H.J. Barrach, V. Pillai, and A.L. Matoney. 1994. Production of type II collagen specific monoclonal antibodies. Immunol. Inv. 23:85–98.
Felice, B.R., C.O. Chichester, and H.J. Barrach. 1999. Type II collagen peptide release from rabbit articular cartilage. Ann. NY Acad. Sci. 878:590–593.
Barrach, H.-J., C.O. Chichester, D.A. Sargetn, M.J. Saracen, S. Griggs, M. Hulstyn, et al. 1996. Quantification of collagen type II peptides in synovial fluid by an inhibition ELISA. Transact. Orthop. Res. Soc. 21:218.
Eyre, D.R., P. Shao, K. Vosberg-Smith, M. Weis, K. Shaffer, and P. Yoshihara. 1996. Cross-linked telopeptides from collagens type I, II and III in human urine. Am. Soc. Bone Min. Res. , Ps413.
Garnero, P., E. Gineyts, S. Christgau, and P.D. Delmas. 1999. Urinary type II collagen C-telepeptide breakdown products as markers of cartilage degradation in rheumatoid arthritis. Arthritis Rheum. 42:S128.
Calvo, M.S., D.R. Eyre, and C.M. Gundberg. 1996. Molecular basis and clinical application of biological markers of bone turnover. Endocr. Rev. 17:333–368.
Atley, L.M., L. Shyarma, J.D. Clemens, K. Shaffer, T.A. Pietka, H.A. Riggins, et al. 2000. The collagen II CTx degradation marker is generated by collagenase 3 and in urine reflects disease burden in knee OA patients. Proc. Orthop. Res. Assoc. 46th Annual Meeting:0168.
Lohmander, L.S., L.M. Atley, T.A. Pietka, and D.R. Eyre. 2000. The release of cross-linked peptides from type II collagen into joint fluid and serum is increased in osteoarthritis and after joint injury. Proc. Orthop. Res. Assoc. 46th Annual Meeting:0236.
Garnero, P., M. Piperno, S. Christgau, P.D. Delmas, and E. Vignon. 2001. Cross-sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann. Rheum. Dis. 60:619–626.
Garnero, P., M. Piperno, E. Gineyts, S. Christgau, P. D. Delmas, and E. Vignon. 2001. Cross-sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann. Rheum. Dis. 60: 619–626.
Mitchell, P.G., H.A. Magna, L.M. Reeves, L.L. Lopresti-Morrow, S.A. Yocum, P.J. Rosner, et al. 1996. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J. Clin. Inv. 97:761–768.
Vankemmelbeke, M., P.M. Dekeyser, A.P. Hollander, D.J. Buttle, and J. Demeester. 1998. Characterization of helical cleavages in type II collagen generated by matrixins. Biochem. J. 330: 633–640.
Stoop, R., P.M. Van Der Kraan, P. Buma, A.P. Hollander, R.C. Billlinghurst, A.R. Poole, et al. 1999. Type II collagen degradation in spontaneous osteoarthritis in C57b1/6 and Balb/c mice. Arthritis Rheum. 42:2381–2389.
Huebner, J.L., I.G. Otterness, E.M. Freund, B. Caterson, and V.B. Kraus. 1998. Collagenase 1 and collagenase 3 expression in a guinea pig model of osteoarthritis [see comments]. Arthritis Rheum. 41:877–890.
Downs, J.T., C.L. Lane, N.B. Nestor, T.J. McLellan, M.A. Kelly, G.A. Karam, et al. 2001. Analysis of collagen cleavage of type II collagen using a neoepitope ELISA. J. Immunol. Meth. 247:25–34.
Andrews, G.C., R.T. Suleske, M.A. Kelly, B.C. Guarino, M.H. Rosner, T.J. McLellan, et al. 2000. Mapping critical amino acids in a linear epitope: A comparison of ELISA methods using a solid state peptide library with a fluorescent polarization solution phase binding assay. Submitted.
Saltarelli, M.J., K. Johnson, E. Pickering, I.G. Otterness, M.D. Vazquez-Abad, and T.G. Woodworth. 1999. Measurement of uninary type II collagen neoepitope levels in rheumatoid arthritis patients to assess joint status. Arthritis Rheum. 42 (Suppl. 9):5249.
Woodworth, T.G., I.G. Otterness, K. Johnson, E. Pickering, and M.J. Saltarelli. 1999. Urinary type II collagen neoepitope in osteoarthritis patients is associated with disease severity. Arthritis Rheum. 42 (Suppl. 9):S258.
Nelson, F., A. Reiner, M. Ionescu, E. Brooks, E. Bogoch, and A.R. Poole. 1994. The content of the C-propeptide of type II collagen in articular cartilage is an index of synthesis of this molecule which is increased in osteoarthritis. Transact. Orthop. Res. Soc. 19:216.
Hinek, A., A. Reiner, and A.R. Poole. 1987. The calcification of cartilage matrix in chon-drocyte culture: studies of the C-propeptide of type II collagen (chondrocalcin). J. Cell Biol. 104: 1435–1441.
Hinek, A. and A.R. Poole. 1988. The influence of vitamin D metabolites on the calcification of cartilage matrix and the C-propeptide of type II collagen (chondrocalcin). J. Bone Mineral Res. 3:421–429.
Shinmei, M., K. Ito, S. Matsuyama, Y. Yoshihara, and K. Matsusawa. 1993. Joint fluid carboxy-terminal type II procollagen peptide as a marker of cartilage collagen biosynthesis. Osteoarth. Cart. 1:121–128.
Lohmander, L.S., Y. Yoshira, H. Roos, T. Kobayashi, H. Yamada, and M. Shinmei. 1966. Changes in joint cartilage aggrecan metabolism after knee injury and in osteoarthritis. Arthritis Rheum. 42:534–544.
Nelson, F., L. Dahlberg, S. Laverty, A. Reiner, I. Pidous, M. Ionescu, et al. 1998. Evidence for altered synthesis of type II collagen in patients with osteoarthritis. J. Clin. Inv. 102:2115–2125.
Wotton, S.F., P.A. Dieppe, and V.C. Duance. 1999. Type IX collagen immunoreactive peptides in synovial fluids from arthritis patients. Rheumatology (Oxford) 38:338–345.
Ratcliffe, A., W. Shurety, and B. Caterson. 1993. The quantitation of native chondroitin sulfate epitope in synovial fluid lavages and articular cartilage from canine experimental osteoarthritis and disuse atrophy. Arthritis Rheum. 36:543–551.
Hazen, P.K., C. Dent, J.A. Fairclough, M.T. Bayliss, and T.E. Hardingham. 1995. Changes in glycosaminoglycan epitope levels in knee joint fluid following injury. Arthritis Rheum. 38:953–959.
Giant, T.T., K. Mikecz, P.J. Roughley, E. Buzaz, and A.R. Poole. 1986. Age-related changes in protein-related epitopes of human articular cartilage proteoglycans. Biochem. J. 236:71–75.
Rizkalla, G., A. Reiner, E. Bogoch, and A. Poole. 1992. Studies of the articular cartilage proteoglycan aggrecan in health and osteoarthritis. Evidence for molecular heterogeneity and extensive molecular changes in disease. J. Clin. Inv. 90:2268–2277.
Lohmander, L.S., M. Ionescu, H. Jugessur, and A.R. Poole. 1999. Changes in joint cartilage aggrecan after knee injury and in osteoarthritis. Arthritis Rheum. 42:534–544.
Poole, A.R., M. Ionescu, A. Swan, and P. Dieppe. 1994. Changes in cartilage metabolism in arthritis are reflected by altered serum and synovial fluid levels of glycosaminoglycan epitopes on fragments of the cartilage proteoglycan aggrecan: implications for pathogenesis. J. Clin. Invest. 94:25–33.
Sweet, M.B.E., A. Coelho, C.M. Schnitzler, T.J. Schnitzer, M.E. Lenz, I. Jaki, et al. 1988. Serum keratan sulfate levels in osteoarthritis patients. Arthritis Rheum. 31:648–652.
Thonar, E.J.-M.A. and T. Glant 1992. Serum keratan sulfate-A marker of predisposition to polyarticular osteoarthritis. Clin. Biochem. 25:175–180.
Champion, G.V., F. McCrai, T.J. Schnitzer, M.E. Lenz, P.A. Dieppe, and E.J.-M.A. Thonar. 1991. Levels of keratan sulfate in the serum and synovial fluid of patients with osteoarthritis of the knee. Arthritis Rheum. 34:1254–1259.
Manicourt, D.H., M.-E. Leny, and E.J.-M.A. Thonar. 1991. Levels of serum keratan sulfate rise rapidly and remain elevated following anterior cruciate ligament transection in the dog. J. Rheumatol. 18:1872–1876.
Thonar, E.J.-M.A., M. Shinmei, and L.S. Lohmander. 1993. Body fluid markers of cartilage changes in osteoarthritis. Rheum. Dis. Clin. North Am. 19:635–657.
Heinegard, D., S. Inerot, J. Wieslander, and G. Lindblad. 1985. A method for the quantification of cartilage proteoglycan structures liberated to the synovial fluid during developing degenerative joint disease. Scand. J. Clin. Lab. Inv. 45:421–427.
Saxne, T., D. Heinegard, and F.A. Wollheim. 1986. Therapeutic effects on cartilage metabolism in arthritis as measured by release of proteoglycan structures into the synovial fluid. Ann. Rheum. Dis. 45:491–497.
Lohmander, L.S., L.A. Hoerrner, L. Dahlberg, H. Roos, S. Björnsson, and M.W. Lark. 1993. Stromelysin, tissue inhibitor of metalloproteinases and proteoglycan fragments in human knee joint fluid after injury. J. Rheumatol. 20:1362–1368.
Lohmander, L.S., L.A. Hoerrner, and M.W. Lark. 1993. Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis. Arthritis Rheum. 36:181–189.
Møller, H.J., F.S. Larsen, T. Ingemann-Hansen, and J.H. Poulsen. 1994. ELISA for the core protein of the cartilage large aggregating proteoglycan, aggrecan: comparison with the concentrations of immunogenic keratan sulfate in synovial fluid, serum and urine. Clin. Chim. Acta 225:43–55.
Hughes, C.E., B. Caterson, A.J. Fosang, P.J. Roughley, and J.S. Mort. 1995. Monoclonal antibodies that specifically recognize neoepitope sequences gererated by “aggrecanase” and matrix metallo-proteinase cleavage of aggrecan: Application to catabolism in situand in vitro. Biochem. J. 305:799–804.
Lark, M.W., E.K. Bayne, J. Flanagan, C.R. Harper, L.A. Hoerrner, N.I. Hutchinson, et al. 1997. Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints. J. Clin. Inv. 100:93–106.
Fosang, A.J., K. Last, P. Gardiner, D.C. Jackson, L. Brown. 1995. Development of a cleavage-site-specific monoclonal antibody for detecting metalloproteinase-derived aggrecan fragments: detection of fragments in human synovial fluids. Biochem. J. 310:2337–2343.
Sharif, M., T. Saxne, L. Shepstone, J.R. Kirwan, C.J. Elson, D. Heinegard, et al. 1995. Relation-ship between serum cartilage oligomeric matrix protein levels and disease progression in osteoarthritis of the knee joint. Br. J. Rheumatol. 34:306–310.
Clark, A.G., J.M. Jordan, V. Vilim, J.B. Renner, A.D. Dragomir, G. Luta, et al. 1999. Serum cartilage oligomeric matrix protein reflects osteoarthritis presence and severity: the Johnston County Osteoarthritis Project. Arthritis Rheum. 42:2356–2364.
Lohmander, L.S., T. Saxne, and D.K. Heinegard. 1994. Release of cartilage oligomeric matrix protein (COMP) into joint fluid after knee injury and in osteoarthritis. Ann. Rheum. Dis. 53:8–13.
Petersson, I.F., T. Boegard, B. Svensson, D. Heinegard, and T. Saxne. 1998. Changes in cartilage and bone metabolism identified by serum markers in early osteoarthritis of the knee joint. Br..J. Rheumatol. 37:46–50.
Johansen, J.S., H.S. Jensen, and P.A. Price. 1993. A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid. Br. J. Rheumatol. 32:949–955.
Harvey, S., M. Weisman, J. O’Dell, T. Scott, M. Krusemeier, J. Visor, et al. 1998. Chondrex: new marker of joint disease. Clin. Chem. 44:509–516.
Volck, B., K. Ostergaard, J.S. Johansen, C. Garbarsch, and P.A. Price. 1999. The distribution of YKL-40 in osteoarthritic and normal human articular cartilage. Scand. J. Rheumatol. 28:171–179.
Cs-Szabo, G., L.I. Melching, P.J. Roughley, and T.T. Glant. 1997. Changes in messenger RNA and protein levels of proteoglycans and link protein in human osteoarthritic cartilage samples. Arthritis Rheum. 40:1037–1045.
Dieppe, P., J. Cushgnaghan, P. Young, and J. Dirwan. 1993. Prediction of the progression of joint space narrowing in osteoarthritis of the knee by bone scintigraphy. Ann. Rheum. Dis. 52:557–563.
Sowers, M., L. Lachance, D. Jamadar, M.C. Hochberg, B. Hollis, M. Crutchfield, et al. 1999. The associations of bone mineral density and bone turnover markers with osteoarthritis of the hand and knee in pre- and perimenopausal women [see comments]. Arthritis Rheum. 42:483–489.
Stewart, A., A. Block, S.P. Robins, and D.M. Reid. 1999. Bone density and bone turnover in patients with osteoarthritis and osteoporosis. J. Rheumatol. 26:622–626.
Thompson, P.W., T.D. Spector, I.T. James, E. Henderson, and D.J. Hart. 1992. Urinary collagen crosslinks reflect the radiographic severity of knee osteoarthritis. Br. J. Rheumatol. 31:759–761.
Sinigaglia, L., M. Varenna, L. Binelli, F. Bartucci, M. Arrigoni, R. Ferrara, et al. 1995. Urinary and synovial pyridinium crosslink concentrations in patients with rheumatoid arthritis and osteoarthritis. Ann. Rheum. Dis. 54:144–147.
MacDonald, A.G., P. McHenry, S.P. Robins, and D.M. Reid. 1994. Relationship of urinary pyridinium crosslinks to disease extent and activity in osteoarthritis [see comments]. Br. J. Rheumatol. 33:16–19.
Graverand, M.P., A.M. Tron, M. Ichou, M.C. Dallard, M. Richard, D. Uebelhart, et al. 1996. Assessment of urinary hydroxypyridinium cross-links measurement in osteoarthritis. Br. J. Rheumatol. 35:1091–1095.
Lohmander, L.S., T. Saxne, and D. Heinegard. 1996. Increased concentrations of bone sialoprotein in joint fluid after knee injury. Ann. Rheum. Dis. 55:622–626.
Petersson, I.F., T. Boegård, J. Dahlstrom, B. Svensson, D. Heinegård, and T. Saxne. 1998. Bone scan and serum markers of bone and cartilage in patients with knee pain and osteoarthritis. Osteoarthritis Cart. 6:33–39.
Lohmander, L.S., H. Roos, L. Dahlberg, L.A. Hoerrner, and M.W. Lark. 1994. Temporal patterns of stromelysin-1, tissue inhibitor, and proteoglycan fragments in human knee joint fluid after injury to the crucuate ligament or meniscus. J. Orthop. Res. 12:21–28.
Beekman, B., J.W. Drijfhout, W. Bloemhoff, H.K. Ronday, P.P. Tak, and J.M. te Koppele. 1996. Convenient fluorometric assay for matrix metalloproteinase activity and its application in biological media. FEBS Lett. 390:221–225.
Keyszer, G., I. Lavviri, R. Nagel, C. Keusser, M. Keysser, E. Gromnica-Ihle, et al. 1999. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1) and MMP-1/TIMP-1 comploex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis. J. Rheumatol. 26:251–258.
Melchiorri, C., R. Meliconi, L. Frizziero, T. Silvestri, L. Pulsatelli, I. Mazzetti, et al. 1998. Enhanced and coordinated in vivo expression of inflammatory cytokines and nitric oxide synthase by chondrocytes from patients with osteoarthritis. Arthritis Rheum. 41:2165–2174.
Manicourt, D.H., P. Vache, A. Egeren, J.-P. Devogelaer, M.E. Lenz, and E.J.-M.A. Thonar. 2000. Synovial fluid levels of tumor necrosis factor a and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan inrheumatoid arthritis but not in osteoarthritis. Arthritis Rheum. 43:281–288.
Koch, A.E., S.L. Kunkel, M.R. Shah, R. Fu, D.D. Mazarakis, G.K. Haines, et al. 1995. Macrophage inflammatory protein-1 beta: a C-C chemokine in osteoarthritis. Clin. Immunol. Immunopath. 77:307–314.
Sharif, M., L. Shepstone, C.J. Elson, P.A. Dieppe, and J.R. Kirwan. 2000. Increased serum C reactive protein may reflect events that precede radiographic progression in osteoarthritis of the knee. Ann. Rheum. Dis. 59:71–74.
Spector, T.D., D.J. Hart, D. Nandra, D.V. Doyle, N. Mackillop, J.R. Gallimore, et al. 1997. Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum. 40:723–727.
Goldberg, R.L., J.P. Huff, M.E. Lenz, P. Glickman, R. Katz, and E.J. Thonar. 1991. Elevated plasma levels of hyaluronate in patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum. 34:799–807.
Manicourt, D.H., O. Cornu, M.E. Lenz, A. Druetz-van Egeren, and E.J. Thonar. 1995. Rapid and sustained rise in the serum level of hyaluronan after anterior cruciate ligament transection in the dog knee joint. J. Rheumatol. 22:262–269.
Lindqvist, U., K. Chichibu, B. Delpech, R.L. Goldberg, W. Knudson, A.R. Poole, et al. 1992. Seven different assays of hyaluronan compared for clinical utility. Clin. Chem. 38:127–132.
Gineyts, E., P. Garnero, and P.D. Delmas. 2001. Urinary excretion of glucosyl-galactosyl puridinoline: a specific biochemical marker of synovium degradation. Rheumatology 40:5–23.
Fraenkel, L., Y. Zhang, S.B. Trippel, T.E. McAlindon, M.P. LaValley, A. Assif, et al. 1998. Longitudinal analysis of the relationship between serum insulin-like growth factor-I and radiographic knee osteoarthritis. Osteoarthritis Cart. 6:362–367.
Verzijl, N., J. DeGroot, S.R. Thorpe, R.A. Bank, J.N. Shaw, T.J. Lyons, et al. 2000. Effect of collagen turnover on the accumulation of advanced glycation end products.. J. Biol. Chem ,275:39
Maroudas, A., M.T. Bayliss, N. Uchitel-Kaushansky, R. Schneiderman, and E. Gilay. 1998. Aggrecan turnover in human articular cartilage: use of aspartic acid racemization as a marker of molecular age. Arch. Biochem. Biophys. 350:61–71.
Sharif, M., C.J. Elson, P.A. Dieppe, and J.R. Kirwan. 1997. Elevated serum C-reactive protein levels in osteoarthritis. Br. J. Rheumatol. 36:140–141.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Humana Press, Inc., Totowa, NJ
About this chapter
Cite this chapter
Otterness, I.G., Saltarelli, M.J. (2002). Using Molecular Markers to Monitor Osteoarthritis. In: Tsokos, G.C. (eds) Modern Therapeutics in Rheumatic Diseases. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-239-5_15
Download citation
DOI: https://doi.org/10.1007/978-1-59259-239-5_15
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4684-9708-3
Online ISBN: 978-1-59259-239-5
eBook Packages: Springer Book Archive